Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Sep 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A-C-Y-W-135 conjugate-Minhai (Primary) ; Hib vaccine conjugate; Meningococcal vaccine group A polysaccharide; Meningococcal vaccine groups A and C conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide
Indications Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Focus Pharmacodynamics; Registrational
Sponsors Beijing Minhai Biotechnology

21 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
14 Dec 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com